Results 31 to 40 of about 10,352 (222)
Objective: Allergen immunotherapy (AIT) and dupilumab have been confirmed to improve symptoms of atopic dermatitis (AD); however, the precise immune mechanisms underlying their efficacy and whether they can elicit synergistic immune effects remain not ...
Jin Liu, MM +11 more
doaj +1 more source
Key Points In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data‐handling processes ...
Marjolein Cornet +10 more
wiley +1 more source
Group 2 innate lymphoid cells (ILCs) are thought to contribute to the pathogenesis of atopic dermatitis (AD). IL-4 stimulates T helper type 2 (Th2) cells and ILC2s to proliferate and produce cytokines. Dupilumab, an antibody against the IL-4 receptor, is
Yasutomo Imai +4 more
doaj +1 more source
Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review
ABSTRACT Background Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.
Andrew Thamboo +28 more
wiley +1 more source
Background Dupilumab is highly effective in atopic dermatitis (AD) but is associated with ocular surface disease, whereas Janus kinase (JAK) inhibitors may have a more favorable ocular safety profile.Objectives To compare ocular outcomes and conjunctival
Paulina Stepinska +2 more
doaj +1 more source
Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis
Background: Eosinophilic otitis media (EOM) is a refractory condition associated with eosinophilic chronic rhinosinusitis and bronchial asthma. EOM is characterized by type-2 inflammation and is refractory to various treatments.
Daiki Nakashima +8 more
doaj +1 more source
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma +12 more
wiley +1 more source
Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear.This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose ...
Koremasa Hayama, M.D., Ph.D. +2 more
doaj +1 more source
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
Background The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12
Jonathan Corren +12 more
doaj +1 more source
ABSTRACT Background To systematically evaluate the local biomarkers correlated with olfactory dysfunction (OD) in chronic rhinosinusitis (CRS). Methods A systematic review was conducted in CINAHL, Cochrane Library, PubMed, and Scopus from inception to July 2025.
David Kayekjian +4 more
wiley +1 more source

